Modern VaccinesAdjuvants Formulation

15-17 May 2013, CHUV, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Poster Session

Poster 101
‘Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells’
Thomas Demoulins, Isabelle Bassi and Kenneth C. McCullough (Institute of Virology and Immunoprophylaxis, Mittelhausern, Switzerland)

Poster 102
‘Emulsified nanoparticles overcomes antigenic competition in a trivalent vaccine formulation containing inactivated virions of influenza, enterovirus and Japanese encephalitis virus’
Ming-His Huang, Chih-Wei Lin, Jui-Yuan Chang, Chia-Chyi Liu, Alan Yung-Chi Hu, Ai-Hsiang Chou and Pele Chong (National Health Research Institutes, Zhunan, Miaoli, Taiwan)

Poster 103
‘Emulsification of recombinant lipoprotein elicits potent immune responses’
Hsin-Wei Chen, Chen-Yi Chiang, Ming-Hsi Huang, Chien-Hsiung Pan, Chun-Hsiang Hsieh, Mei-Yu Chen, Hsueh-Hung Liu, Jy-Ping Tsai, Shih-Jen Liu, Pele Chong and Chih-Hsiang Leng (National Institute of Infectious Diseases and Vaccinology, Miaoli, Taiwan)

Poster 104
‘Development of the intranasal RSV F subunit vaccine SynGEM®’
Natalija Van Braeckel-Budimir, Kees Leenhouts, Bert Jan Haijema, Ivy Widjaja and Alan Rigter, Xander de Haan and Peter Rottier (Mucosis BV, Groningen, The Netherlands)

Poster 105
‘Nanocarriers for DNA vaccination: Simultaneous TLR9 and NLR2 stimulation leads to synergistic enhancement of pro-inflammatory cytokine release from murine macrophages’
J. Poecheim et al. (University of Geneva/University of Lausanne, Geneva, Switzerland)

Poster 106
‘Development of novel nanoparticle-based vaccines and immunotherapies: Tuberculosis, lung metastasis and allergy as models’
Marie Ballester et al. (EPFL, Lausanne, Switzerland)

Poster 107
‘Matrix-M™ adjuvanted West Nile virus envelope protein vaccine leads to protection against experimental West Nile virus infection’
Sofia E. Magnusson et al. (Isconova AB, Uppsala, Sweden)

Poster 108
‘Robust adjuvant formulations for stable vaccines’
Juliette Ben Arous et al. (SEPPIC, Puteaux, France)

Poster 109
‘Harnessing innate immunity to design novel adjuvant formulations that enhance vaccine immunogenicity in multiple animal species: The case for CpG-ODN’
Sharath K. Rai et al. (Zoetis Inc., Kalamazoo, Michigan, USA)

Poster 110
‘Development and in vitro evaluation of cell culture adapted thermostable Newcastle disease vaccine in Pakistan’
Faisal Siddique et al. (University of Agriculture, Faisalabad, Pakistan)

Poster 111
‘Evaluation of immune response to measles vectored & Pichica Pastoris expressed recombinant HPV vaccine formulations’
Gaurav Gupta et al. (Cadila Healthcare Ltd, Ahmedabad, India)

Poster 112
‘Emulsified nanoparticles containing TLR9 agonist inducing anti-tumor immunity’
Shih-Jen Liu et al. (National Institute of Infectious Diseases and Vaccinology, Miaoli, Taiwan)

Poster 113
‘Saponin-containing nanoparticles as an efficient adjuvant system for influenza vaccine mucosal immunization’
V.E. Berezin et al. (Institute of Microbiology & Virology, Almaty, Kazakhstan)

Poster 114
‘Recombinant liposome-based OspC experimental vaccine with lipophilic derivatives of norAbuMDP’
Josef Masek et al. (Veterinary Research Institute, Brno, Czech Republic)

Poster 115
‘Liposomal formulations of norAbuMDP/GMDP as immunomodulators and adjuvants’
Jaroslav Turanek et al. (Veterinary Research Institute, Brno, Czech Republic)

 

MVAF 2013 Delegates

Login details will be supplied after you have registered for the event.


MVAF 2013 Sponsors

  • Aldevron
  • Viscogel
  • Intercell
  • Novartis Vaccines
  • Immune Solutions
  • Vironova
  • Dynavax
  • Pharvat
  • Izon
  • Seppic
  • Immune Design
  • Vedantra Pharmaceuticals
  • IDRI
  • Wittycell
  • Brenntag
  • Inovio
  • Retroscreen Virology
  • Vaccine Formulation Laboratory
  • Pfizer
  • Sanofi Pasteur
  • DNA Vaccine
  • European Adjuvant Advisory Committee
  • Mucosis
  • Univac
  • CSL

MVAF 2013 Downloads

MVAF 2013 Leaflet

MVAF 2013 Mailing List

Name
E-mail Address
What is 1+4-2?